000292156 001__ 292156
000292156 005__ 20241111182445.0
000292156 0247_ $$2doi$$a10.3390/cancers16152711
000292156 0247_ $$2pmid$$apmid:39123440
000292156 0247_ $$2pmc$$apmc:PMC11311363
000292156 0247_ $$2altmetric$$aaltmetric:166501675
000292156 037__ $$aDKFZ-2024-01644
000292156 041__ $$aEnglish
000292156 082__ $$a610
000292156 1001_ $$0P:(DE-He78)34bd069ab74ead9ac824c1e0896ecbf0$$aAngelova, Assia Ludmilova$$b0$$eFirst author$$udkfz
000292156 245__ $$aH-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma.
000292156 260__ $$aBasel$$bMDPI$$c2024
000292156 3367_ $$2DRIVER$$aarticle
000292156 3367_ $$2DataCite$$aOutput Types/Journal article
000292156 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1723464264_8152
000292156 3367_ $$2BibTeX$$aARTICLE
000292156 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292156 3367_ $$00$$2EndNote$$aJournal Article
000292156 500__ $$a#EA:D490#LA:D490#
000292156 520__ $$aThe rat protoparvovirus H-1 (H-1PV) is an oncolytic virus known for its anticancer properties in laboratory models of various human tumors, including non-Hodgkin lymphomas (NHL) of B-cell origin. However, H-1PV therapeutic potential against hematological malignancies of T-cell origin remains underexplored. The aim of the present study was to conduct a pilot preclinical investigation of H-1PV-mediated oncolytic effects in cutaneous T-cell lymphoma (CTCL), a type of NHL that is urgently calling for innovative therapies. We demonstrated H-1PV productive infection and induction of oncolysis in both classically grown CTCL suspension cultures and in a novel, in vivo-relevant, heterotypic spheroid model, but not in healthy donor controls, including peripheral blood mononuclear cells (PBMCs). H-1PV-mediated oncolysis of CTCL cells was not prevented by Bcl-2 overexpression and was accompanied by increased extracellular ATP release. In CTCL spheroid co-cultures with PBMCs, increased spheroid infiltration with immune cells was detected upon co-culture treatment with the virus. In conclusion, our preclinical data show that H-1PV may hold significant potential as an ingenious viroimmunotherapeutic drug candidate against CTCL.
000292156 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000292156 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292156 650_7 $$2Other$$acutaneous T-cell lymphoma (CTCL)
000292156 650_7 $$2Other$$aheterotypic CTCL spheroid
000292156 650_7 $$2Other$$aoncolytic H-1 parvovirus
000292156 650_7 $$2Other$$avirotherapy
000292156 7001_ $$0P:(DE-He78)3cd3b4ba1b77b32c7d862b50a7a4a60d$$aBarf, Milena$$b1$$udkfz
000292156 7001_ $$0P:(DE-He78)75a948e2a369ddd0d4f3c1c07f833da3$$aJust, Alexandra$$b2$$udkfz
000292156 7001_ $$0P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f$$aLeuchs, Barbara$$b3$$udkfz
000292156 7001_ $$0P:(DE-He78)2d7958ea507b0b738619074b38ec6d54$$aRommelaere, Jean$$b4$$udkfz
000292156 7001_ $$0P:(DE-He78)833f90e2abdd29594ad5c4f08600f191$$aUngerechts, Guy$$b5$$eLast author$$udkfz
000292156 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers16152711$$gVol. 16, no. 15, p. 2711 -$$n15$$p2711$$tCancers$$v16$$x2072-6694$$y2024
000292156 8564_ $$uhttps://inrepo02.dkfz.de/record/292156/files/cancers-16-02711-v2.pdf
000292156 8564_ $$uhttps://inrepo02.dkfz.de/record/292156/files/cancers-16-02711-v2.pdf?subformat=pdfa$$xpdfa
000292156 8767_ $$83099318$$92024-07-26$$d2024-11-11$$eAPC$$jZahlung erfolgt$$pcancers-3099318
000292156 909CO $$ooai:inrepo02.dkfz.de:292156$$pVDB$$pOpenAPC$$popenCost
000292156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34bd069ab74ead9ac824c1e0896ecbf0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000292156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3cd3b4ba1b77b32c7d862b50a7a4a60d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75a948e2a369ddd0d4f3c1c07f833da3$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000292156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)119d7d540a0e6fc5734898bef4866d7f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000292156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d7958ea507b0b738619074b38ec6d54$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000292156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)833f90e2abdd29594ad5c4f08600f191$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000292156 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000292156 9141_ $$y2024
000292156 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000292156 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000292156 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000292156 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000292156 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000292156 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000292156 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000292156 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000292156 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000292156 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000292156 9202_ $$0I:(DE-He78)D490-20160331$$kD490$$lKKE Virotherapie$$x0
000292156 9201_ $$0I:(DE-He78)D490-20160331$$kD490$$lKKE Virotherapie$$x0
000292156 9201_ $$0I:(DE-He78)D430-20160331$$kD430$$lVirus-assoziierte Karzinogenese$$x1
000292156 9201_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x2
000292156 9200_ $$0I:(DE-He78)D490-20160331$$kD490$$lKKE Virotherapie$$x0
000292156 980__ $$ajournal
000292156 980__ $$aVDB
000292156 980__ $$aI:(DE-He78)D490-20160331
000292156 980__ $$aI:(DE-He78)D430-20160331
000292156 980__ $$aI:(DE-He78)Z999-20160331
000292156 980__ $$aUNRESTRICTED
000292156 980__ $$aAPC